Thyroid carcinoma: Molecular pathways and therapeutic targets

Modern Pathology

Volumn 21, Issue , 2008, Pages S37-S43

  Nikiforov, Yuri E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

BRAF; Inhibitors; MAPK; Mutations; RET; Thyroid cancer

Indexed keywords

AAL 881; B RAF KINASE; LBT 613; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SORAFENIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX8; VANDETANIB;

ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CANCER MODEL; CANCER RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLICULAR CARCINOMA; GENE MUTATION; GENE REARRANGEMENT; HUMAN; MEDULLARY CARCINOMA; NONHUMAN; PAPILLARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROTO ONCOGENE; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL; REVIEW; THYROID CARCINOMA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 42549088683     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.10     Document Type: Article

References (74)

1. Hundahl SA, Fleming ID, Fremgen AM, et al. A national cancer data base report on 53 856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 1998;83:2638-2648.
2. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457.
3. Fagin JA. Genetics of papillary thyroid cancer initiation: Implications for therapy. Trans Am Clin Climatol Assoc 2005;116:259-269; discussion 269-271.
4. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev 2006;6: 292-306.
5. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-627.
6. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-262.
7. Ciampi R, Nikiforov YE. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 2005;16:163-172.
8. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-867.
9. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006;30:216-222.
10. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-5404.
11. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-4397.
12. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90: 6373-6379.
13. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in lowrisk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006;65:364-368.
14. - targeting to the membrane. Endocr Relat Cancer 2006;13:257-269.
15. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004;202: 247-251.
16. Carta C, Moretti S, Passeri L, et al. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf) 2006;64:105-109.
17. Hou P, Liu D, Xing M. Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 2007;6: 377-379.
18. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005;115: 94-101.
19. Begum S, Rosenbaum E, Henrique R, et al. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol 2004;17:1359-1363.
20. Fusco A, Grieco M, Santoro M, et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987;328:170-172.
21. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-563.
22. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002;13:3-16.
23. Tallini G, Asa SL. REToncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 2001;8:345-354.
24. Santoro M, Dathan NA, Berlingieri MT, et al. Molecular characterization of RET/PTC3; A novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994;9:509-516.
25. Knauf JA, Kuroda H, Basu S, et al. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 2003;22:4406-4412.
26. Santoro M, Melillo RM, Grieco M, et al. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ 1993;4:77-84.
27. Jhiang SM, Sagartz JE, Tong Q, et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996;137:375-378.
28. Santoro M, Chiappetta G, Cerrato A, et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 1996;12:1821-1826.
29. Powell Jr DJ, Russell J, Nibu K, et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 1998;58:5523-5528.
30. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005;115:1068-1081.
31. Mitsutake N, Knauf JA, Mitsutake S, et al. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 2005;65: 2465-2473.
32. Zhu Z, Ciampi R, Nikiforova MN, et al. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 2006;91: 3603-3610.
33. Unger K, Zitzelsberger H, Salvatore G, et al. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4272-4279.
34. Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997;57:1690-1694.
35. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990;4:1474-1479.
36. Ezzat S, Zheng L, Kolenda J, et al. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 1996;6:409-416.
37. Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003;120:71-77.
38. Hara H, Fulton N, Yashiro T, et al. N-ras mutation: An independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 1994;116: 1010-1016.
39. Lemoine NR, Mayall ES, Wyllie FS, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989;4: 159-164.
40. Suarez HG, du Villard JA, Severino M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990;5:565-570.
41. Motoi N, Sakamoto A, Yamochi T, et al. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract 2000;196: 1-7.
42. Basolo F, Pisaturo F, Pollina LE, et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 2000;10:19-23.
43. Garcia-Rostan G, Zhao H, Camp RL, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003;21:3226-3235.
44. Fagin JA. Minireview: Branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 2002;16:903-911.
45. Saavedra HI, Knauf JA, Shirokawa JM, et al. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 2000;19:3948-3954.
46. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000;289:1357-1360.
47. French CA, Alexander EK, Cibas ES, et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 2003;162:1053-1060.
48. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003;88:2318-2326.
49. Dwight T, Thoppe SR, Foukakis T, et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 2003;88:4440-4445.
50. Nikiforova MN, Biddinger PW, Caudill CM, et al. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 2002;26:1016-1023.
51. Gregory Powell J, Wang X, Allard BL, et al. The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene 2004;23:3634-3641.
52. Giordano TJ, Au AY, Kuick R, et al. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res 2006;12:1983-1993.
53. Reddi HV, McIver B, Grebe SK, et al. The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis. Endocrinology 2007;148:932-935.
54. Mulligan LM, Marsh DJ, Robinson BG, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: Report of the International RET Mutation Consortium. J Intern Med 1995;238:343-346.
55. Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: From neoplasia to neurogenesis. J Med Genet 2000;37:817-827.
56. Santoro M, Melillo RM, Carlomagno F, et al. Molecular biology of the MEN2 gene. J Internal Med 1998;243: 505-508.
57. Alberti L, Carniti C, Miranda C, et al. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 2003;195:168-186.
58. Eng C, Mulligan LM, Healey CS, et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 1996;56: 2167-2170.
59. Herbst RS, Heymach JV, O’Reilly MS, et al. Vandetanib (ZD6474): An orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007;16:239-249.
60. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-7290.
61. Santoro M, Carlomagno F. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract 2006;2:42-52.
62. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004;23:6056-6063.
63. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and nonsmall-cell lung cancer: Current knowledge and future directions. J Clin Oncol 2005;23:2556-2568.
64. Carlomagno F, Vitagliano D, Guida T, et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002;62:1077-1082.
65. Carlomagno F, Vitagliano D, Guida T, et al. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3, 4-d]pyrimidine (PP2). J Clin Endocrinol Metab 2003;88:1897-1902.
66. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070-4076.
67. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
68. Salvatore G, De Falco V, Salerno P, et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623-1629.
69. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-334.
70. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007;8:148-156.
71. Espinosa AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br J Cancer 2007;96:16-20.
72. Ouyang B, Knauf JA, Smith EP, et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 2006;12:1785-1793.
73. Chiloeches A, Marais R. Is BRAF the Achilles’ Heel of thyroid cancer? Clin Cancer Res 2006;12: 1661-1664.
74. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-362.